Abstract 2806 Background: A high degree of prognostic certainty is required to recommend
or discourage high risk treatment procedures in primary myelofibrosis (PMF). The Dynamic …

Allogeneic stem cell transplantation (alloSCT) is the only curative treatment option for
patients with high-risk myelofibrosis (MF). However, it is important to bear in mind that …

Purpose The Dynamic International Prognostic Scoring System (DIPSS) for primary
myelofibrosis (PMF) uses five risk factors to predict survival: age older than 65 years …

Objective To share our decades of experience with primary myelofibrosis and underscore
the importance of outcomes research studies in designing clinical trials and interpreting their …

To define a prognostic model for predicting outcome of reduced‐intensity allogeneic stem
cell transplantation (RIC‐ASCT) for myelofibrosis we evaluated 150 homogenously treated …

In this cross-sectional study, we retrospectively evaluated the files of 227 patients with
myelofibrosis who underwent transplantation between 1994 and 2015 for relapse later than …

Among the myeloproliferative diseases, myelofibrosis is a widely heterogeneous entity
characterized by a highly variable prognosis. In this context, several prognostic models have …

Modifications of transplant-conditioning regimens have reduced transplant-related mortality
and allow carrying out successful HCT in increasingly older patients. The selection of …

Optimal conditioning regimens for older patients with myelofibrosis undergoing allogeneic
hematopoietic cell transplant are not known. Likewise, the role of dose intensity is not clear …

Primary myelofibrosis (PMF) is a Philadelphia chromosome–negative chronic
myeloproliferative neoplasm usually affecting elderly people. Median survival currently …